High B-cell-activating factor levels in endemic Tunisian pemphigus
Sir, B-cell-activating factor belonging to the tumor necrosis factor family plays a crucial role in B-cell development, immunoglobulin production and switch to the IgG, IgE and IgA subclasses. Excessive B-cell-activating factor rescues self-reactive B cells from anergy which may play a crucial role in the induction and development of autoimmunity. Previous reports have shown elevated serum B-cell-activating factor levels in patients with systemic lupus, Sjögren syndrome and rheumatoid arthritis. 1 Pemphigus is an autoimmune intraepidermal blistering disease characterized by the presence of autoantibodies against desmoglein 1 in pemphigus foliaceus and desmoglein 3 in pemphigus vulgaris.
Knowing that B-cell-activating factor pathway is involved in the generation of autoreactive B cells, we analyzed serum B-cell-activating factor levels in Tunisian pemphigus vulgaris and pemphigus foliaceus patients and correlated their levels with clinical presentation and autoantibody profile. This is a cross-sectional retrospective study on frozen samples at −80°C. Sera were obtained from 50 pemphigus foliaceus patients and 36 pemphigus vulgaris patients with a median age of 44 years (range 17-81). All patients fulfilled clinical and immunological criteria of pemphigus. Forty pemphigus foliaceus patients as well as 29 pemphigus vulgaris patients had recurrent, active disease; the other patients were in remission. Blood sample was collected before corticosteroid treatments in 28 pemphigus foliaceus and 22 pemphigus vulgaris patients. Among pemphigus patients with recurrent, active disease, 9 pemphigus foliaceus and 14 pemphigus vulgaris patients were under systemic therapy at the time of drawing the blood to perform serum B-cell-activating factor measurement. The retrospective nature of the study limited the clinical data concerning severity of the diseases for 27 pemphigus foliaceus and 28 pemphigus vulgaris patients from the case records. For these patients, we evaluated the severity of pemphigus according to the cutaneous and mucosal involvement of defined areas of the body -score 0 (no lesions), score 1 (<25% involvement), score 2 (25%-50%), score 3 (50%-75%) and score 4 (>75%). Thirty eight healthy controls with a median age of 43 years were also recruited in the study. This investigation was approved by the ethical committee of La Rabta University Hospital. All patients and controls gave their consents for the study.
Pemphigus foliaceus and pemphigus vulgaris patients as well as healthy control were already tested for anti-desmoglein 1 and 3 autoantibodies (MBL, Nagoya, Japan) and the presence of autoantibodies other than anti-desmoglein. 3 A specific enzyme-linked immunosorbent assay kit was used to measure serum B-cell-activating factor levels (R&D Systems Inc., Minneapolis, USA). Values above the mean ± 2 standard deviation (1168 pg/ml) in control samples were considered as high levels.
Statistical analysis was performed using the Statistical Package for Social Sciences, version 16.0 (SPSS Inc., Chicago, IL, USA). P < 0.05 was considered statistically significant.
In healthy control, serum B-cell-activating factor levels ranged between 200 and 1200 pg/ml with a mean value of 748 ± 206 pg/ml. Serum B-cell-activating factor mean values did not differ between the three groups (pemphigus foliaceus, pemphigus vulgaris and healthy control), yet we note a P value (P = 0.052) near the threshold of significance. However, after Bonferroni correction, serum B-cell-activating factor levels were significantly higher in pemphigus foliaceus patients (mean level 982 ± 557 pg/ml) than in healthy control, P = 0.046. There was no statistically significant difference between pemphigus vulgaris patients and healthy control [ Figure 1 ].
High serum B-cell-activating factor levels were observed in 14 (28%) pemphigus foliaceus and 11 (30.5%) pemphigus vulgaris patients.
In pemphigus foliaceus patients, serum B-cell-activating factor levels were significantly higher in those without corticosteroid treatment (mean level 1229 ± 573 pg/ml) than in healthy control (P < 0.001 by t-test). Moreover, mean serum B-cell-activating factor values were significantly higher in patients with high score disease severity (P = 0.012 by t-test) and in those with the recurrent active disease before re-introduction of corticosteroid or any other treatment (P < 0.001 by t-test) [ Table 1 ].
In pemphigus foliaceus patients, scores for disease severity were available for seven and twenty cases with high and low serum B-cell-activating factor, respectively. Among the seven pemphigus foliaceus patients with high serum B-cell activating factor, all (100%) had widespread disease (score of disease severity 3-4) compared to nine of twenty patients (45%) in those with normal serum B-cell-activating factor (P = 0.02 by Fisher's exact test).
In pemphigus vulgaris patients, scores for disease severity were available for 7 and 21 cases with high and low serum B-cell-activating factor, respectively. Among the seven pemphigus vulgaris patients with high serum B-cell activating factor, only 4 (57%) showed severe lesions compared to 6 of 21 (28%) of those with normal serum B-cell-activating factor.
Although serum B-cell-activating factor levels did not correlate with age, stratification of patients according to the mean age revealed that younger pemphigus foliaceus patients had significantly higher levels.
In both groups, there was no significant correlation between serum B-cell activating factor neither with anti-desmoglein 1/desmoglein 3 autoantibodies titers nor with the presence of autoantibodies other than anti-desmoglein.
Unlike previous studies, our findings revealed the presence of a significant difference among autoimmune pemphigus patients and controls. 2, 4 Matsushita et al. did not find a significant difference between pemphigus or pemphigoid patients and the control group regarding serum B-cell-activating factor levels. 2 Asashima et al. reported a significant difference in bullous pemphigoid, but not in pemphigus vulgaris patients. 4 In this study, we found that serum B-cell activating factor values were significantly higher in pemphigus foliaceus patients than in healthy control. Interestingly, significant associations between serum B-cell-activating factor values, younger age and clinical status (absence of corticosteroid treatment and disease activity) were found only in the pemphigus foliaceus group. In Tunisia, pemphigus has particular epidemiological features: pemphigus foliaceus is the endemic form of the disease; it is predominantly observed in women of the reproductive age group. These patients have common human leukocyte antigen susceptibility alleles which vary from the ones observed in the sporadic form in the north of the country. 5 Thus, B-cell activating factor elevation occurs mainly in patients with Tunisian endemic pemphigus features. Serum B-cell activating factor mean levels were found to be significantly lower in patients under corticosteroid treatment. This effect is different from that seen in rituximab-treated patients. 6 In this study, we failed to find a significant correlation between anti-desmoglein 1/desmoglein 3 autoantibodies titers and serum B-cell-activating factor, while in systemic lupus erythematosus, a strong association was found between anti-deoxyribonucleic acid antibodies titers and serum B-cell-activating factor values. Moreover, serum B-cell-activating factor levels in Tunisian systemic lupus erythematosus cases are significantly higher compared to those found in Tunisian pemphigus foliaceus patients (2340.72 ± 1000 pg/ml, unpublished data).
The presence of high levels of serum B-cell-activating factor suggests that this cytokine induces the expansion of activated B and T cells and autoantibodies production. This overexpression, significantly observed in the absence of treatment mainly on the earlier onset of pemphigus foliaceus, suggests that serum B-cell-activating factor participated in the proliferation of autoreactive cells, thus enhancing the autoimmune response. Besides, it has been reported that B-cell-activating factor acts on dendritic cells helping them to increase the pro-inflammatory activity of T cells. This is in accordance with the association of high serum B-cell-activating factor levels with high score disease in pemphigus foliaceus. This data may reflect serum B-cell-activating factor contributing to pemphigus pathogenesis.
Interestingly, B-cell-activating factor polymorphism −871C/T is involved in pemphigus foliaceus pathogenesis. 7 Analyzing the association of this polymorphism in our patients and assessing its functional impact are needed to investigate the biological Figure 1 : Comparison of serum B-cell-activating factor mean levels (pg/ml) in pemphigus patients (pemphigus foliaceus (PF), pemphigus vulgaris (PV)) and in healthy controls (HC). Significant difference (P < 0.05) was observed with pemphigus foliaceus patients when compared to healthy control (serum B-cell-activating factor means are in red lines). BAFF: B-cell activating factor, NS: Not significant significance of serum B-cell-activating factor elevation in pemphigus foliaceus patients. Targeting B-cell-activating factor with monoclonal antibodies (belimumab) has been approved for systemic lupus erythematosus treatment, but clinical and theoretical arguments for a potential beneficial effect in pemphigus are lacking. 8 In conclusion, we described the presence of higher levels of serum B-cell-activating factor in pemphigus foliaceus patients. These levels correlated with disease activity in patients without treatment. Because this finding is mainly observed in patients with features of the endemic form of Tunisian pemphigus foliaceus, it needs to be confirmed in other endemic forms of pemphigus within homogeneous and comparable age repartition and disease duration. Answering this question will clarify whether the autoimmune mechanisms through serum B-cell-activating factor varies among pemphigus forms and possibly making the endemic forms distinct. 
A study on various Neisseria gonorrhoeae phenotypes circulating in Tripura
Sir, Gonorrhea is one of the most common sexually transmitted infections in the developed world caused by the Gram-negative diplococcus Neisseria gonorrhoeae. Once an easily treatable disease, it has become a therapeutic problem owing to coinfections, asymptomatic infections, misdiagnosis and antibiotic misuse leading to multidrug resistance. There was lack of epidemiologic data from Tripura on the frequency of disease and drug resistance patterns, which encouraged us to conduct this study which would help to identify the circulating drug resistant phenotypes and thereby determine the drugs effective in the local population.
The study was conducted at Agartala Government Medical College, Agartala, Tripura, between July 2013 and June 2015 after receiving clearance from the Institutional Ethical Committee. Two hundred and seventy five subjects suspected to have clinically compatible features of sexually transmitted infections in the reproductive age group of 18-49 years attending the dermatology or the obstetrics and gynecology clinics were included in the study. Direct Gram-stain of urethral/cervical smear was performed followed by culturing on chocolate agar (HiMedia Laboratories, Mumbai, India). Identification was done as per standard protocol. Chlamydia trachomatis screening was done using polymerase chain reaction. 1 For diagnosis of human immunodeficiency virus infection, National Acquired Immune Deficiency Syndrome Control Organization guideline of strategy III was followed. Antimicrobial susceptibility testing was performed against penicillin G, tetracycline, ciprofloxacin, nalidixic acid, azithromycin, spectinomycin and ceftriaxone through E-test and Kirby-Bauer disc diffusion methods. Modified Hodge test was carried out among the resistant phenotypes. 2 Briefly, 
